{"classes":[{"categories":[{"measurements":[{"comment":"The data was not estimable as the samples were BLLQ.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"The data was not estimable as the samples were BLLQ.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"title":"Predose, Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"182","value":"20.7"},{"groupId":"OG001","spread":"251","value":"22.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"title":"3 hours Post-dose, Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"56","value":"73.9"},{"groupId":"OG001","spread":"50","value":"74.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"138"}],"units":"Participants"}],"title":"Predose, Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"78","value":"69.9"},{"groupId":"OG001","spread":"65","value":"73.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"title":"Predose, Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55","value":"96.7"},{"groupId":"OG001","spread":"62","value":"98.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"131"}],"units":"Participants"}],"title":"3 hours Post-dose, Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"111","value":"58.5"},{"groupId":"OG001","spread":"90","value":"66.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"title":"Predose, Cycle 2 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received inavolisib, 9 mg, orally, QD on Days 1-28 of each 28 day cycle along with palbociclib 125 mg, orally, QD on Days 1-21 and fulvestrant, 500 mg, IM injections on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28 day cycle until unequivocal disease progression, unacceptable toxicity, participant withdrawal of consent, or study termination.","id":"OG000","title":"Inavo+Palbo+Fulv"},{"description":"Participants received placebo, orally, QD on Days 1-28 of each 28 day cycle along with palbociclib 125 mg, orally, QD on Days 1-21 and fulvestrant, 500 mg, IM injections on Days 1 and 15 of Cycle 1 and then of Day 1 of each subsequent 28 day cycle until unequivocal disease progression, unacceptable toxicity, participant withdrawal of consent, or study termination.","id":"OG001","title":"Pbo+Palbo+Fulv"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK evaluable population included all participants who received at least one dose of study drug, had at least one post-baseline sample, and was based on the treatment participants actually received. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Predose on Cycle 1 Days 1, 8 and 15 and Cycle 2 Day 15; 3 hours post-dose on Cycle 1 Days 1 and 15 (Cycle length = 28 days)","title":"Plasma Concentration of Palbociclib","type":"SECONDARY","unitOfMeasure":"ng/ml"}